Kingworld Medicines Group Management
Management Kriterienprüfungen 3/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Li Sheng Zhao
Geschäftsführender
CN¥1.5m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 98.5% |
| Amtszeit als Geschäftsführer | 16.2yrs |
| Eigentum des Geschäftsführers | 54.0% |
| Durchschnittliche Amtszeit des Managements | keine Daten |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 14yrs |
Jüngste Management Updates
Recent updates
Kingworld Medicines Group (HKG:1110) Takes On Some Risk With Its Use Of Debt
Oct 04
Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0338
May 31Even With A 26% Surge, Cautious Investors Are Not Rewarding Kingworld Medicines Group Limited's (HKG:1110) Performance Completely
May 22Investors Shouldn't Be Too Comfortable With Kingworld Medicines Group's (HKG:1110) Earnings
Apr 29Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0338
Apr 23A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)
Mar 22The Return Trends At Kingworld Medicines Group (HKG:1110) Look Promising
Nov 30Slowing Rates Of Return At Kingworld Medicines Group (HKG:1110) Leave Little Room For Excitement
Aug 17Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0247
May 30The Returns At Kingworld Medicines Group (HKG:1110) Aren't Growing
May 11Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0247
Apr 03Returns On Capital At Kingworld Medicines Group (HKG:1110) Paint A Concerning Picture
Feb 07A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)
Oct 07Kingworld Medicines Group's (HKG:1110) Returns On Capital Not Reflecting Well On The Business
Jul 05Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To HK$0.024
Apr 27We Like These Underlying Return On Capital Trends At Kingworld Medicines Group (HKG:1110)
Aug 17Kingworld Medicines Group (HKG:1110) Seems To Use Debt Rather Sparingly
Apr 24Returns On Capital Are Showing Encouraging Signs At Kingworld Medicines Group (HKG:1110)
Mar 29Kingworld Medicines Group's (HKG:1110) Shareholders Are Down 46% On Their Shares
Mar 08Are Insiders Buying Kingworld Medicines Group Limited (HKG:1110) Stock?
Feb 15Should You Or Shouldn't You: A Dividend Analysis on Kingworld Medicines Group Limited (HKG:1110)
Jan 25
Will the Promising Trends At Kingworld Medicines Group (HKG:1110) Continue?
Dec 18We Think Kingworld Medicines Group (HKG:1110) Can Stay On Top Of Its Debt
Dec 05What We Learned About Kingworld Medicines Group's (HKG:1110) CEO Compensation
Nov 22Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥31m |
| Mar 31 2024 | n/a | n/a | CN¥35m |
| Dec 31 2023 | CN¥1m | CN¥1m | CN¥38m |
| Sep 30 2023 | n/a | n/a | CN¥37m |
| Jun 30 2023 | n/a | n/a | CN¥36m |
| Mar 31 2023 | n/a | n/a | CN¥29m |
| Dec 31 2022 | CN¥1m | CN¥1m | CN¥23m |
| Sep 30 2022 | n/a | n/a | CN¥29m |
| Jun 30 2022 | n/a | n/a | CN¥35m |
| Mar 31 2022 | n/a | n/a | CN¥33m |
| Dec 31 2021 | CN¥1m | CN¥1m | CN¥30m |
| Sep 30 2021 | n/a | n/a | CN¥26m |
| Jun 30 2021 | n/a | n/a | CN¥21m |
| Mar 31 2021 | n/a | n/a | CN¥17m |
| Dec 31 2020 | CN¥1m | CN¥1m | CN¥12m |
| Sep 30 2020 | n/a | n/a | CN¥16m |
| Jun 30 2020 | n/a | n/a | CN¥20m |
| Mar 31 2020 | n/a | n/a | CN¥32m |
| Dec 31 2019 | CN¥2m | CN¥2m | CN¥43m |
| Sep 30 2019 | n/a | n/a | CN¥45m |
| Jun 30 2019 | n/a | n/a | CN¥46m |
| Mar 31 2019 | n/a | n/a | CN¥44m |
| Dec 31 2018 | CN¥1m | CN¥1m | CN¥41m |
| Sep 30 2018 | n/a | n/a | CN¥49m |
| Jun 30 2018 | n/a | n/a | CN¥56m |
| Mar 31 2018 | n/a | n/a | CN¥54m |
| Dec 31 2017 | CN¥2m | CN¥1m | CN¥51m |
Vergütung im Vergleich zum Markt: Li ShengDie Gesamtvergütung ($USD202.28K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt Hong Kong ($USD236.00K).
Entschädigung vs. Einkommen: Li ShengDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Li Sheng Zhao (66 yo)
16.2yrs
Amtszeit
CN¥1,452,000
Vergütung
Mr. Li Sheng Zhao is a Co-founder of Kingworld Medicines Group Limited and serves as its Chief Executive Officer. Mr. Zhao is responsible for Kingworld Medicines Group's overall strategic planning and busi...
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Co-Founder | 16.2yrs | CN¥1.45m | 54.04% HK$ 157.1m | |
| Co-Founder & Executive Director | 16.2yrs | CN¥1.32m | 15.23% HK$ 44.3m | |
| Executive Director | 15.3yrs | CN¥483.00k | 0.45% HK$ 1.3m | |
| Independent Non-Executive Director | 14yrs | CN¥285.00k | 0.036% HK$ 103.9k | |
| Independent Non-Executive Director | 14yrs | CN¥285.00k | keine Daten | |
| Independent Non-Executive Director | 11.3yrs | CN¥285.00k | 0.042% HK$ 121.5k | |
| Independent Non-Executive Director | less than a year | keine Daten | keine Daten |
14.0yrs
Durchschnittliche Betriebszugehörigkeit
61yo
Durchschnittliches Alter
Erfahrener Vorstand: 1110Die Vorstandsmitglieder sind sehr erfahren ( 14 ).